Tier 3 — preclinical

Efficacy and Safety of Two Chondroprotective Supplements in Patients With Knee Osteoarthritis: A Randomized, Single-Blind, Pilot Study

Piercarlo Minoretti, Andrés Santiago Sáez, Miryam Liaño Riera, Manuel Gómez Serrano, Ángel García Martín
Cureus 2024 16(4):e57579

Bibliography

PubMed
PMID 38707049
PubMed Central
PMC11069075
DOI
10.7759/cureus.57579
Competing interests
The authors declared no competing interests.

Study snapshot

DesignRandomized, single-blind, three-arm pilot study
ModelAdults with mild-to-moderate knee osteoarthritis
Samplen=51; 17 per group
InterventionSyalox 300 Plus: HA 300 mg + Boswellia serrata 100 mg daily versus glucosamine/chondroitin/curcuminoid supplement versus no treatment
Duration4 weeks
EndpointsPain at rest; Pain during movement; Range of motion; WOMAC; Serum adropin; Adverse events

What the study showed, in plain terms

The HA/Boswellia arm improved pain and WOMAC outcomes and outperformed the glucosamine/chondroitin/curcumin comparator on several pain measures. Because each group was small and the HA product also contained Boswellia, the result is supportive combination evidence, not an isolated HA trial.

Key findings

What this study can and cannot tell us

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology